In the area of inflammatory bowel diseases (IBD), a group of chronic autoimmune disorders affecting the digestive tract, the introduction of monoclonal antibodies (MAbs) targeting TNF-α marked a significant advancement. Here, TNF is linked to inflammatory bowel disease.